Caladrius Biosciences (NASDAQ:CLBS) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.20, Fidelity Earnings reports.
CLBS stock traded down $0.68 during trading on Friday, reaching $4.53. 21,628 shares of the stock traded hands, compared to its average volume of 36,147. Caladrius Biosciences has a 52-week low of $2.91 and a 52-week high of $11.65. The company has a market cap of $47.56 million, a PE ratio of -2.54 and a beta of 1.22.
A number of research firms have issued reports on CLBS. Chardan Capital reissued a “buy” rating on shares of Caladrius Biosciences in a research report on Wednesday, August 29th. Zacks Investment Research raised Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a research report on Wednesday, September 12th. Finally, HC Wainwright boosted their price target on Caladrius Biosciences to $15.00 and gave the company a “buy” rating in a research report on Monday, September 10th.
Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.
Featured Story: Do Tariffs Work?
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.